Calidi Biotherapeutics, Inc. (CLDI): Entry into a Material Definitive Agreement
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 GENESIS MOREHOUSE AT 5580 LEASE BP3-SD4 5580 MOREHOUSE DRIVE LLC, a Delaware limited liability company, as Landlord, and CALIDI BIOTHERAPEUTICS, INC., a Delaware corporation, as Tenant SUMMARY OF BASIC LEASE INFORMATION This Summary of Ba
How this was made
The 30-second read
Why it matters
The lease creates fixed operating cost commitments (base rent escalators) and requires a letter of credit, which can matter for a small-cap biotech’s cash runway. However, the excerpt does not include funding, debt, or operational milestones tied to the lease.
Market read
A material lease agreement with defined rent schedule and a letter of credit is disclosed, which can affect near-term liquidity expectations but lacks clinical or financing catalysts.
What to watch
Traders may be underweighting the liquidity effect of the letter of credit and any tenant improvement obligations, but those details are not included in the scraped excerpt.
Background
The SEC 8-K reports Item 1.01 entry into a material definitive agreement and includes an exhibit summarizing a new lease for Calidi Biotherapeutics.
Ticker impact
Calidi Biotherapeutics filed an 8-K disclosing entry into a material definitive lease agreement with specified rent, term, and letter of credit.
Likely limited near-term impact; any reaction would be modest and sentiment-driven unless the lease terms materially change liquidity expectations.
The newest disclosed facts are lease commencement (Oct 1, 2026), term (44 months), base rent schedule, and a $113,574.78 letter of credit. No revenue, guidance, or financing terms are provided, so the trading signal is primarily cost/obligation related rather than fundamental re-rating.
Market effects
Adds a small data point on biotech real-estate cost structure, but no sector-wide read-across is provided.
Local San Diego office footprint change; no broader regional market signal in the text.
No global macro or cross-border implications disclosed.
Counterpoint
The lease could be a strategic move to support operations, and the disclosed letter of credit may be routine for the company’s stage, limiting downside impact.
Key entities
- issuerCLDI
Calidi Biotherapeutics, Inc., the tenant entering the lease agreement disclosed in the 8-K.
- counterpartyBP3-SD4 5580 Morehouse Drive LLC
Landlord entity in the lease exhibit.
- brokerJones Lang LaSalle Brokerage, Inc.
Landlord broker named in the lease summary.
- brokerSavills
Tenant broker named in the lease summary.
